At a glance
- What the study gets you
- Health checks and monitoring — no treatment given
- Type of study
- Observational (no treatment given)
- Time in hospital
- In-person visits at study sites — visit count not specified by the sponsor
- Drug or intervention
- Not specified by the sponsor
- How long the study runs
- Study runs about 59 months (dates as stated)
- About the drug or intervention
- Not specified by the sponsor
- Patient visit burden
- Not specified by the sponsor
In plain English
This study, run by Imperial College London, looks at people aged 16 and over with colorectal cancer (cancer of the bowel). It is investigating whether something called EMVI (when tumour cells are seen in blood vessels near the tumour on scans) can help tell if the cancer may spread.
Who can take part
- Aged 16 or over with colorectal cancer
- The colon or rectum has been removed by surgery
- Cancer that had spread to other parts of the body has been removed by surgery
- Scans (CT or MRI) were done before surgery and the images are available to review
Who may not be able to
- No cancer cells were found in the main tumour after treatment (a complete response)
- The main tumour was removed using a local resection (a smaller operation)
- Not enough tissue sample available to carry out the study tests
What taking part involves
- • Not stated — ask the trial team
Time commitment: Not stated — ask the trial team
Plain-English summary (AI-generated) from registry data. Not eligibility advice — only the trial team can confirm whether you can take part. Use the eligibility checker to see how your health profile matches this trial.
- Type of study
- Observing health over time
- Ages
- 16 Years to 100 Years
- Who
- All
- Number of participants
- 100
- Started
- 2023-01-01
- Last checked
- 2024-10
Plain English Summary
What is this study?
- • Testing a new treatment for colo-rectal cancer
- • Clinical study - 100 participants
- • Bowel cancer is the fourth most commonly occurring cancer and the second highest cause of cancer deaths in the UK
Who can take part?
- • Ages 16 Years to 100 Years
- • Diagnosed with colo-rectal cancer
Where?
- • Basingstoke - Hampshire Hospitals Nhs Foundation Trust
This is a simplified summary. Always discuss with your doctor before making any decisions.
About This Trial
Bowel cancer is the fourth most commonly occurring cancer and the second highest cause of cancer deaths in the UK. Despite advances in treatment, over 40% of patients will die within 5 years. This is normally due to spread of the cancer to other organs (called metastases). Much of the current research focuses on use of additional treatments such as radiotherapy and chemotherapy before or after surgery (adjuvant treatment). It is of vital importance that patients who would benefit from adjuvant treatment can be accurately identified. At the moment, the system used locally to do this places emphasis on the presence of affected lymph nodes (glands). This is because doctors believe that cancer spreads to other organs through the lymphatic system. However, recent studies have suggested that this is not the case. It is believed that cancer spreads to other organs through the blood stream rather than the lymph node system. This research will look at the genetic material in tumours and metastases as well as in areas of blood vessel invasion and lymph nodes. The analysis will allow us to build a 'family tree' of the tumour and allow us to map the pathway by which the tumour spreads. Tissue samples already collected through a patient's routine care will be used for this study. If the spread through the blood vessels is proven, this would change the way in which patients are selected for treatment and allow development of new treatments to target these pathways.
More detail
A retrospective ,non-interventional tissue study using archival materials collected through a patient's routine care, EVIDENCE aims to demonstrate that distant metastases in colorectal cancer are related to Extramural Venous Invasion (EMVI) and tumour deposits, not lymph nodes. As EVIDENCE is a retrospective study, there are no time dependent schedules for Case Report Form (CRF) completion or tissue submission. It will be tested whether the vascular route of spread (as evidenced through EMVI and tumour deposits) is more important than lymph nodes in the development of metastatic disease. The sub-clonal origins of primary colorectal cancers, EMVI, tumour deposits, lymph nodes and distant metastases by reconstructing phylogenetic trees will be compared. A proof for a vascular route of spread rather than lymph nodes would lead to a paradigm shift in future decision making at national and international level.
How this trial compares with your answers
Answer 2 more questions to improve match
What we know so far
Still need:
- • Tell us your age for better matching
- • Tell us your sex for better matching
Preliminary match based on your answers. Full eligibility requires on-site assessment including medical history, physical exam, and lab tests. This does not guarantee enrolment.
Eligibility at a Glance
Key info
- Age: 16 Years - 100 Years
- Who can join: All genders
What the study is looking for
- ✓Are aged 16 years or over with colorectal cancer
- ✓Colon / rectum has been surgically removed
- ✓Distant metastases has been surgically removed
- ✓Pre operative staging in the form of CT/MRI has been undertaken and images available for review
Who cannot take part
- ✗Pathological complete response in the primary tumour
- ✗Local resection of the primary tumour
- ✗Inadequate quantity of tissue sample to perform analyses
See the full criteria
Where Is This Study? (1 UK site)
Hampshire Hospitals Nhs Foundation Trust
Basingstoke RG24 9NA, United Kingdom
How to Get in Touch
Caroline Martin
Sponsor contactCONTACT
Syvella Ellis
Sponsor contactCONTACT